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Expanding the therapeutic options for renal involvement in lupus: Eculizumab, 
available evidence  
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AIM: To systematically review available literature on the efficacy of eculizumab for the 
treatment of renal involvement in patients with systemic lupus erythematosus (SLE)  
METHODS: We conducted a literature search developed a priori, to identify articles reporting 
clinical experience with the use of eculizumab in SLE patients, focusing on renal involvement. 
The search strategy was applied to Ovid MEDLINE, In-Process and Other Non-Indexed Citation, 
EMBASE, Cochrane Central Register of Controlled Trials and Scopus from 2002 (year of the first 
publication retrieved ever indexed in Pubmed using “eculizumab” as search term) to present. 
Abstracts from EULAR and ACR congresses were also screened. 
RESULTS: We included 6 publications describing the renal outcome in SLE patients receiving 
eculizumab. Five out of six cases described the occurrence of thrombotic microangiopathy 
(TMA) in renal biopsies of patients with known SLE;3 cases with biopsy-proven lupus 
nephritis (LN) and 2 patients with SLE-related antiphospholipid syndrome without histologic 
evidence of LN. One study reported the outcome of a patient with severe refractory LN 
successfully treated with eculizumab. All patients, regardless of the presence of concomitant 
LN, presented with severe hypocomplementemia and renal function impairment. All patients 
showed a sustained improvement of renal function and normalization of complement 
parameters after treatment with eculizumab[median follow-up 9 months (1-17)].  
CONCLUSION: Despite the limitations of the currently available evidence, existing data are 
promising and provide preliminary support for the use of eculizumab in selected cases of SLE 
with renal involvement, especially in the presence of TMA, or in patients with refractory LN. 
Keywords: lupus nephritis, eculizumab, complement, systemic lupus erythematosus, 
antiphospholipid antibody 
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Introduction 
Systemic lupus erythematosus (SLE) pathogenesis is rooted in dysregulation of the immune 
system [1][2][3]. Reduced thresholds of B and T cell activation induce loss of self tolerance 
and production of autoantibodies [4][5][6] while impaired clearance of apoptotic cells and 
immune complexes is responsible for their deposition and consequent activation of 
inflammatory pathways resulting in tissue damage [7][3][8].  
Complement is a fundamental component of the innate immune system and plays a crucial 
rolein modulating the adaptive immune response [9],influencing T-cell activation [10], natural 
antibody development [11] and auto-reactive B-cell regulation [12].  
Alternative pathways (e.g. formation of the C3 convertase complex) and terminal components 
of complement activation (C5-C9) are believed to play a relevant role in the pathogenesis of 
lupus nephritis (LN) [9][12][13][14]. Additionally, genetic or acquired deficiencies of certain 
components of the classical complement pathways (C1q, C2 or C4) [8][15] or of lectin 
pathway (mannose-binding lectin) [16] are responsible for rare forms of SLE. Similarly, 
mutations in complement inhibitor factors such as complement factor H have been associated 
with SLE, in particular with LN[17].   
Eculizumab is a recombinant fully humanized IgG2/IgG4 monoclonal antibody that blocks the 
formation of the terminal complex sC5b-9 and C5a by binding to the C5 complement 
component and consequently blocking the activation pathway [18]. Eculizumab has been 
approved for patients with paroxysmal nocturnal hemoglobinuria(PNH) and atypical 
hemolytic uremic syndrome (aHUS) [18][19].Growing evidence from in vitro and in vivo 
studies suggest a promising role for eculizumab for the treatment of other autoimmune 
[20][21][22][23][24][25]and primary renal diseases. 
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Treatment with eculizumab has been shown to significantly reduce proteinuria and renal 
dysfunction and prolong survival in a lupus-prone New Zealand Black/New Zealand White 
(NZB/W) murine model[14]. In addition,  eculizumab has been successfully used to prevent 
recurrences of catastrophic antiphospholipid antibody syndrome (CAPS) in a kidney recipient 
[26] and to induce remission in a patient with type II membranoproliferative 
glomerulonephritis.[27]. Recently, a pilot randomized controlled trial showed that eculizumab 
treatment may stabilize renal function in chronic antibody mediated injury in kidney 
transplant recipients [28]. 
Against this background, in addition to aHUS and PNH, this drug may prove to be efficacious 
for patients with certain types of glomerulopathies. However, the efficacy of eculizumab for 
the treatment of LN remains to be demonstrated. 
Methods 
We performed a detailed literature search, developed a priori, to identify and include in our 
study articles that reported clinical experience with the use of eculizumab in SLE patients 
with renal involvement. Key words and subject terms used in the search included: 
("eculizumab"[Supplementary Concept] OR "eculizumab"[All Fields]) AND ("lupus 
erythematosus, systemic"[MeSH Terms] OR ("lupus"[All Fields] AND "erythematosus"[All 
Fields] AND "systemic"[All Fields]) OR "systemic lupus erythematosus"[All Fields] OR 
("systemic"[All Fields] AND "lupus"[All Fields] AND "erythematosus"[All Fields]). 
The search strategy was applied to Ovid MEDLINE, In-Process and Other Non-Indexed Citation, 
EMBASE, Cochrane Central Register of Controlled Trials and Scopus from 2002 (year of the first 
publication retrieved ever indexed in Pubmed using “eculizumab” as search term) to present; 
abstracts from EULAR and ACR were also screened. Studies that met the above mentioned 
criteria were systematically analyzed by two independent reviewers (MR and SS). 
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Disagreements were resolved by consensus; if consensus could not be achieved, a third party 
(IC) provided an assessment of eligibility. As the data on eligibility were dichotomous 
(eligible: yes/no), inter-rater agreement at both the title and abstract review and the full 
article review stages was determined by calculation of Cohen’s kappa coefficient (k=0.89).  
Results 
Characteristics of retrieved studies are summarized in Table 1. Five out of six cases described 
the occurrence of thrombotic microangiopathy (TMA) in the renal biopsies of patients with an 
underlying diagnosis of SLE. Of those, 3 patients had TMA lesions in association with LN 
histological characteristics in the absence ofanti-phospholipid antibodies (aPL)[29][30][31] 
and 2 patients had SLE-related antiphospholipid syndrome without histologic evidence of 
LN[32][33]. Finally, one study reported the outcome of a patient with severe refractory LN 
successfully treated with eculizumab[34].  
All patients underwent previous immunosuppressive treatments as listed in Table 1and five 
out of six (all those with TMA) had received plasmapheresis. Eculizumab was introduced 
either because of lack of efficacy or due to adverse reactions to  immunosuppressive 
agents.[31][32][33][34][30][29][29].  
All patients, regardless of the presence of concomitant LN, presented with severe 
hypocomplementemia and renal function impairment. Histological findings on renal biopsy 
are shown in Table 1. Patients showed a sustained improvement of renal function and 
normalization of complement parameters after treatment with eculizumab. In 3 cases, renal 
flares were observed after eculizumab discontinuation and improvement in renal parameters 
was observed after re-initiation of eculizumab. Normalization of platelets counts and 
haptoglobulin were also reported. Response to eculizumab seems to be sustained during the 
follow-up period [median 9 months (1-17)]. 
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None of the studies reported adverse events attributed to eculizumab. One patient developed 
retrocardiac pneumonia with moderate pleural effusion due to Streptococcus pneumoniae. 
Meropenem was introduced and eculizumab temporarily stopped[29].  
Discussion 
Conventional treatments for SLE are usually directed against the adaptive immune response 
by limiting T and B cell activation, and/or lowering auto-antibody production. Targeting the 
complement pathway and consequently limiting the inflammatory response unleashed by tissue 
deposition of auto-antibodies and immune complexes may represent an alternative treatment 
strategy in SLE in some clinical manifestations of SLE. In our literature search we found an 
overall successful response to eculizumab in patients with TMA and SLE. Thrombotic 
microangiopathy has been significantly associated with antiphospholipid antibodies (aPL) 
and represents the hallmark histologic lesion of the aPL-associated nephropathy detected in 
both primary APS and SLE patients[35][36]. Canaud et al. also reported a successful use of 
eculizumab in three consecutive kidney transplant recipients with post-transplant TMA due 
to aPL-associated nephropathy recurrence that was resistant to plasmaphereisis [37]. Lonze 
et al. [26], also described the case of a patient with TMA in the context of primary Catastrophic 
APS (CAPS)who was successfully treated with eculizumab to prevent CAPS relapses before a 
renal transplantation. 
However, besides the successful use of complement inhibition to prevent or reverse TMA, in 
two cases[29][34]improvement in renal function was also observed after eculizumab use in 
the context of active LN. Of note, in one of those patients, improvement in renal function was 
seen in the absence of TMA on renal biopsy [34].  
Eculizumab has been shown to inhibit complement-mediated TMA in aHUS patients 
(resolving thrombocytopenia and TMA) and to improve renal transplantation outcomes by 
allowing plasma exchange-dependent patients to stop this treatment [19]. It has been also 
 7 
used off-label in TTP patients refractory to treatment with plasma exchange. In the light of 
these observations, eculizumab may be a potential treatment option in refractory SLE patients 
with TMA (with or without aPL).It is biologically plausible that targeting different pathogenic 
mechanisms (with steroids/standard immunosuppression, anticoagulation, plasmapheresis 
and complement inhibition) may improve the prognosis and the management of SLE. The 
treatment of patients with features of renal thrombotic microvascular involvement coexisting 
with LN can be challenging and often requiresan aggressive approach. In fact, TMA in patients 
with SLE is frequently associated with poor renal outcomes [38] and, in the presenceof aPL, 
may lead to irreversible end-stage renal failure[38].As eculizumab has already been used to 
control PNH and aHUS during pregnancy[39,40], it could represent a further tool to manage 
renal flares in the setting of pregnancy, when many immunosuppressive agents are 
contraindicated. Indeed, renal flares (including new onset of TMA) are not uncommon during 
pregnancy [41]and negatively impact pregnancy outcomes[42].  
However, despite these promising observations, some considerations are warranted.  
The efficacy of eculizumab for the treatment of SLE remains to be determined. Furie et al. [43] 
enrolled 24 SLE patients in a single center, randomized, placebo-controlled, double-blind, 
dose ranging phase I study. This trial failed to demonstrate significant efficacy of eculizumab, 
as determined by laboratory and clinical parameters or SLEDAI scores. It is important to note 
that phase I studies are not powered to determine efficacy of new experimental therapies. In 
addition, the majority of patients had low disease activity. However, in this trial, no adverse 
events were observed related to eculizumab and there was no significant human antibody 
response. 
In conclusion, despite the limitations of the currently available evidence presented here (low 
number of patients, potential publication bias with studies reporting only positive outcomes, 
heterogeneity in clinical presentation, renal histologic findings, and applied protocols), 
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available data are promising and provide preliminary support for targeting complement 
pathways in SLE.  Future studies should evaluate whether eculizumab represents an 
additional therapeutic option in the treatment of selected cases of SLE with renal 
involvement, especially in the presence of TMA, or in patients with refractory LN. 
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Key messages.  
 Renal involvement occurs in 40% of SLE patients, with ESKD developing in 15% of 
them  
 Therapeutic options are needed for SLE patients intolerant/resistant to conventional 
therapy or during gestation 
 Complement plays a crucial role in modulating the adaptive immune response in 
patients with SLE  
 Eculizumab may be considered in selected cases of SLE with renal involvement, TMA,  
refractory LN 
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